Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.

1 Medizinische Klinik Klinikum Bremen Mitte Bremen Germany

2 Medizinische Klinik und Poliklinik Universitätsklinikum Schleswig Holstein Kiel Germany

2 Medizinische Klinik Universitätsklinikum Eppendorf Hamburg Germany

3 Medizinische Klinik Medizinische Fakultät Mannheim Universität Heidelberg Mannheim Germany

Ambulante Hämatologie und Onkologie Bonn Germany

Barmherzige Brüder Regensburg Germany

Caritas Krankenhaus Lebach Germany

Charitè Berlin Germany

Diakonie Schwäbisch Hall Germany

Ev Krankenhaus Hamm Germany

Hämatologische Onkologische Schwerpunktpraxis Würzburg Germany

IBE Universität München Munich Germany

Innere Medizin 1 Universitätsklinikum Freiburg Germany

Inselspital Bern Switzerland

Institut für Humangenetik MHH Hanover Germany

Internistische Schwerpunktpraxis Erlangen Germany

Kantonsspital Aarau Switzerland

Klinik 1 für Innere Medizin Universitätsklinikum Köln Germany

Klinik für Hämatologie und medizinische Onkologie Universitätsmedizin Göttingen Germany

Klinik für Innere Medizin 1 Universität des Saarlandes Homburg Germany

Klinik für Innere Medizin 2 Universitätsklinikum Jena Germany

Klinik für innere Medizin 3 Chemnitz Germany

Klinik für Innere Medizin 3 Universitätsklinikum Ulm Germany

Klinik für Innere Medizin 3 Westpfalz Klinikum Kaiserslautern Germany

Klinik für innere Medizin Universitätsklinikum Marburg Germany

Klinik für Knochenmarktransplantation Essen Germany

Klinik für Onkologie und Hämatologie Oldenburg Germany

Klinik und Poliklinik für Innere Medizin 3 Universitätsklinikum Regensburg Germany

Klinikum Schwabing Munich Germany

Masaryk University Hospital Brno Czech Republic

Medizinische Abteilung 2 Universitätsklinikum Tübingen Germany

Medizinische Klinik 2 Herford Germany

Medizinische Klinik 3 Städtisches Klinikum Karlsruhe Germany

Medizinische Klinik 3 Universität Bonn Germany

Medizinische Klinik 3 Universität München Munich Germany

Medizinische Klinik 5 Klinikum Nürnberg Nord Nürnberg Germany

Medizinische Klinik 5 Universität Heidelberg Heidelberg Germany

Medizinische Klinik 5 Universitätsklinikum Erlangen Germany

Medizinische Klinik A Universitätsklinikum Münster Germany

Medizinische Klinik und Poliklinik Universitätsklinikum Würzburg Germany

MLL Munich Germany

Onkologie Leer UnterEms Leer Germany

Onkologie Zentrum Ansbach Germany

Onkologische Schwerpunktpraxis Bielefeld Germany

Onkologische Schwerpunktpraxis Heilbronn Germany

Praxisklinik für Hämatologie und Onkologie Koblenz Germany

RWTH Aachen Germany

St Antonius Hospital Eschweiler Germany

St Marien Hospital Hagen Germany

St Marien Krankenhaus Siegen Germany

Stauferklinikum Schwäbisch Gmünd Mutlangen Germany

Universitätsspital Basel Switzerland

Vivantes Klinikum Neukölln Berlin Germany

Komentář v

Haematologica. 2019 May;104(5):862-864. doi: 10.3324/haematol.2018.214445. PubMed

Zobrazit více v PubMed

O'Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004. PubMed

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017; 376: 917–927. PubMed PMC

Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Mueller MC, Pletsch N et al. Tolerability-adapted imatinib 800mg/d versus 400mg/d versus 400mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634–1642. PubMed

Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096–2102. PubMed

Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood 2015; 126: 42–49. PubMed PMC

Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118: 6760–6768. PubMed

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol 2015; 94: 2015–2024. PubMed

Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415–423. PubMed

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511–2521. PubMed

Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A et al. Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011; 118: 3228–3235. PubMed

Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E et al. Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009; 113: 4497–4504. PubMed

Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28: 424–430. PubMed PMC

Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol 2014; 99: 616–624. PubMed

Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E et al. Imatinib 800mg daily induces deeper molecular responses than imatinib 400mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 2014; 164: 223–232. PubMed PMC

Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600mg/day of imatinib as initial therapy. Blood 2008; 112: 3965–3973. PubMed

Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 2015; 125: 915–923. PubMed PMC

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C et al. Final 5-Year Study Results of DASISION: The Dasatinib versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 2016; 34: 2333–2340. PubMed PMC

Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044–1054. PubMed PMC

Gratwohl A, Pfirrmann M, Zander A, Kroger N, Beelen D, Novotny J et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia 2016; 30: 562–569. PubMed PMC

Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820. PubMed

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872–884. PubMed PMC

Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858. PubMed

Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016; 30: 48–56. PubMed

Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172–2175. PubMed

Branford S, Fletcher L, Cross NCP, Müller MC, Hochhaus A, Kim D-W et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330–3338. PubMed

Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118: 1208–1215. PubMed

Dupont WD. PS power and sample size program available for free on the internet. Controlled Clin Trial 1997; 18: 274.

Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38: 163–170. PubMed

Shkolnikov V, Barbieri M, Wilmoth J. The Human Mortality Databasehttp://www.mortality.org/.

Pfirrmann M, Lauseker M, Hoffmann VS, Hasford J. Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. Ann Hematol 2015; 94: S209–S218. PubMed

Pfirrmann M, Hochhaus A, Lauseker M, Sausele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 2011; 25: 1433–1438. PubMed

Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141–1154.

Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710–719. PubMed

Pohar M, Stare J. Relative survival analysis in R. Comput Methods Programs Biomed 2006; 81: 272–278. PubMed

Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–799. PubMed

Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686–692. PubMed

Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A et al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol 2014; 140: 1965–1969. PubMed PMC

Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT, Heinrich L et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 29: 1123–1132. PubMed

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 2016; 17: 612–621. PubMed

Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029–1035. PubMed

Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV